Pharmacology of Vaccines against Coronavirus Disease in Clinical Use Globally: A Review
Published: 2023-08-02
Page: 153-162
Issue: 2023 - Volume 6 [Issue 1]
Casimir C. Ofor *
Department of Pharmacology and Therapeutics, Faculty of Basic Clinical Sciences, College of Health Sciences, Ebonyi State University, Abakaliki, Nigeria.
Godwin C. Akuodor
Department of Pharmacology and Therapeutics, Faculty of Basic Clinical Sciences, College of Health Sciences, Nnamdi Azikiwe University, Nnewi Campus, Nigeria.
Eugene O. Ohanme
Department of Pharmacology and Therapeutics, Faculty of Basic Clinical Sciences, Alex Ekwueme Federal University, Abakaliki, Ebonyi State, Nigeria.
Chikere Anusiem
Department of Pharmacology and Therapeutics, College of Medicine, University of Nigeria, Enugu Campus, Nigeria.
*Author to whom correspondence should be addressed.
Abstract
Following the lethal nature of the coronavirus disease and the high transmissibility of the disease, a concerted effort has been made throughout the world to produce viable and affordable vaccines to curb the impact of the disease globally. Various technologies have employed in the process of developing vaccines against the coronavirus disease. Adverse events following immunization is very common in patients receiving immunological and biological products. These events are characterized by some serious clinical manifestations in the patients.
Over three thousand, five hundred adverse events reports were made by clients receiving some coronavirus vaccines in the United States of America by the center for disease control in June, 2021. Some of the features manifested by the patients include: convulsions, irregular heart beats, serious abdominal discomfort and signs resembling cerebrovascular accidents.
Well over one thousand case reports of inflammation of the heart muscles and the pericardium were reported to the Vaccine Adverse Events Reporting system following the inoculation with mRNA-based coronavirus vaccine produced by Moderna and Pfizer-BioNtech pharmaceutical companies in the United States of America (USA) according to the CDC reports in April, 2021.
Keywords: Coronavirus vaccine, SARS-Cov2, immunology, disease, adverse events
How to Cite
Downloads
References
Attia S, Howaldt HP. Impact of COVID-19 on the dental community: Part I Before Vaccine (BV). Clin. Med. 2021;10:288.
Leidner AJ, Murthy N, Chesson HW, Biggerstaff M, Stoecker C, Harris AM, Acosta A, Dooling K, Bridges CB. Cost-effectiveness of adult vaccinations: A systematic review. Vaccine. 2019;37:226-234. [PubMed]
Gavi the Vaccine Alliance. There are Four Types of COVID-19 Vaccines: Here's How They Work. #VaccinesWork; 2021.
Available:https://wwvv.gavi.org/vaccineswork/there-are-four-types-covi.d-19-vaccines-heres-how-they-work
Access on 29 July 2021
European Medicines Agency (EMA). Authorised COVID-19 Vaccines. COVID-19; 2021.
Available:https://www.ema.europa.eu/en /human-regulatory/overview/public-health- threats/coronaviras-disease-covid-19/ treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised#authorised-covid-19-vaccines-section
Access on 29 July 2021
Bettini, E, Locci M. SARS-CoV-2 mRNA vaccines: Immunological mechanism and beyond. Vaccines. 2021;9:147. [PubMed]
Dong Y, Dai X, Wei Y, Zhang L, Zheng M, Zhou F. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct. Target. Ther. 2020;5:237.
Divya S, Fahima Sheerin SMH, Chindhiha S, Selvakumar K. Worldmeter coronavims update (live). Int. J. Recent Acad. Res. 2020;2:610-614.
Paul-Ehrlich-Institute. Coronavims und COVID-19; 2021.
Available:https://www.pei.de/DE/newsroom/dossier/coronavims/coronavirus-inhalt.html Access on 7 July 2021
Nohl A, Afflerbach C, Lurz C, Brune B, Ohmann X, Weichert V, Zeiger S, Dudda M. Acceptance of COVID-19 vaccination among front-line health care workers: A nationwide survey of emergency medical services personnel from Germany. Vaccines. 2021;9:424. [PubMed]
Ministerio da Saude (BR), Secretaria deVigilancia em Saude, Departamento de Imunizacoes e DoengasTransmissfveis. Manual deVigilancia Epidemiologica de Eventos Adversos Pos-Vacinacao. Brasilia, DF; 2020.
World Health Organization. Council for International Organizations of Medical Sciences. Definition and application of terms for vaccine pharmacovigilance: report of ClOMS/WHO Work Group on Vaccine Pharmacovigilance. 2012. Geneva: WHO/CIOMS.
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and namingit SARS-CoV-2. Nat Microbiol. 2020;5(4): 536-544.
Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021;21(2):73-82.
World Health Organization. GACVS COVID-19 Vaccine Safety subcommittee meeting to review reports of deaths of very frail elderly individuals vaccinated with Pfizer BioNTech COVID-19 vaccine, BNT162b2. Geneva: WHO; 2021
Available:https://www.who.int/news/ item/22-01-202l-gacvs-review-deaths-pfizer-biontech-covid-19-vaccine-bnt162b2 Access on 2021 Feb 22
Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol. 2020;1:585354.
Chung YH, Beiss V, Fiering SN, Steinmetz NF. COVID-19 vac¬cine frontrunners and their nanotechnology design. ACS Nano. 2020;14(10):12522-12537.
Lee P, Kim CU, Seo SH, Kim DJ. Current status of COVID-19 vaccine development: Focusing on antigen design and clinical trials on later stages. Immune Netw. 2021;21(l):e4.
McGill COVID19 Vaccine Tracker Team. Vaccines Candidates by Trial Phase; 2021.
Available:https://covid19.trackvaccines.org/vaccines/?fbclid=IwAR0rJdUx1T1j9TalYCJzwvnqm6MWluN2wwWtnu DP0GW6YvKLh3nW-Ex0ZKU. Access on 27 June 2021
Jordan R, Barrett JR, Belij-Rammerstorfer S, et al. Phase ½ trial SARS-Cov-2 vaccine ChAdox1 nCov-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021;17(2):279-288.
Folegatti PM, Ewer KJ, Aley PK et al. Safety and immunogenicity of the ChAdOxl nCov-19 vaccine against SARS-Cov-2: a preliminary report of a ½, single-blind, randomized controlled trial. Lancet. 2020; 396(10249):467-478.
Xia S, Zhang Y, Wang Y et al. Safety and immunogenicity of an inactivated SARS-Cov-2 vaccine, BBIBP-CorV: A randomized double-blind, placebo-controlled phase ½ trials. Lancetninfect Dis. 2021;21(1):39-51.
Silva RBD, Silva TPRD, Sato APS, Lana FCF, Gusmão JD, Souza JFA, Matozinhos FP. Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais. Rev Saude Publica. 2021;55:66.
DOI:10.11606/s1518-8787.2021055003734 PMID: 34706042; PMCID: PMC8522717
Oliver S, Gargano J, Marin M, et al. The Advisory Committee on Immunization Practices' interim recommendation for use of Moderna COVID-19 vaccine-United States, December 2020. MMWR Morb Mortal Wkly Rep. 2021;69:1653-1656.
Ramasamy MM, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOxl nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021:396:1979-1993. Available:https://doi.org/10.1016/S0140-6736(20)32466-l
Centers for Disease Control and Prevention (). Allergic reactions including anaphylaxis after receipt of the first dose of moderna COVID-19 vaccine—United States, December 21,2020-January 10; 2021. Available:https://www.cdc.gov/mmwr/volumes/70/wr/mm7004el. html Access on 8 Jul 2021
Moderna. Moderna announces primary efficacy analysis in phase 3 COVE study for its COVID-19 vaccine candi¬date and filing today with U.S. FDA for emergency use authorization: Moderna, Inc; 2020.
Klugar M, Riad A, Mekhemar M, Conrad J, Buchbender M, Howaldt HP, Attia S. Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccine among German Healthcare Workers. Biology (Basel). 2021;10(8):752.
DOI: 10.3390/biology10080752 PMID:34439984;PMCID:PMC8389568
Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and immuno¬genicity of SARS-coV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383(25):2427-38.
Available:https://doi.org/10. U)56/NEJMoa2028436
Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, et al. Durability of responses after SARS-coV-2 mRNA-1273 vaccination. N Engl J Med; 2020. Available:https://doi.org/10.1056/NEJMc2032195
United States Food and Drug Administration. Pfizer-BioNTech COVID-19 vaccine; 2021.
Available:https://www.fda.gov/emergcncy-prepa redness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine Access on 3 Jul 2021
Sellaturay P, Nasser S, Islam 5, Gurugama P, Ewan P. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine. Clin Exp Allergy; 2021. Available:https://doi.org/10.1111/cea.13874
MMWR2 allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 Vaccine - United States. December 21, 2020-January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(4):125-129.
Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vac¬cine. JAMA. 2021;325(8):780.
Wenande W, Garvey LH. Immediate type hypersensitivity to poly¬ethylene glycols: A review. CEA. 2016;46:907-922.
Lu IN, Rutkowski K, Kennard L, et al. Polyethylene glycol may be the major allergen in depot medroxyprogesterone acetate. J Allergy Clin Immunol Pract. 2020;8:3194-3197.
Kennard L, Rutkowski K, Mirakian R, Wagner A. Polyethylene glycol: not just a harmless excipient. J Allergy Clin Immunol Pract. 2018;6:2173.
Stone CA, Yiwei L, Relling MV, et al (2019). Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized. JACI Pract. 2019;7:1533-1540.
Li PH, Wagner A, Thomas I, et al (2020). Steroid allergy: clinical features and the importance of excipient testing in a diagnostic algorithm. J Allergy Clin Immunol Pract. 2018;6:1655-2166.
Rutkowski K, Wagner A, Rutkowski R. Immediate hypersensitivity reactions to steroids and steroid containing medications. Curr Opin Allergy Clin Immunol;20:362-366.